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Summary 
Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability in 
Australia. About 1 in 13 people aged 40 and over have lung function consistent with a 
diagnosis of COPD (Toelle et al. 2013). The disease develops over many years and therefore 
mainly affects middle-aged and older people. Smoking is its main, but not only, cause.  
Current clinical guidelines for the management of COPD (developed by the Thoracic Society 
of Australia and New Zealand and Lung Foundation Australia) emphasise the importance of 
care that encompasses both drug and non-drug based interventions designed to improve 
quality of life and survival. 
Pulmonary rehabilitation is a system of care that includes a combination of exercise, 
education and psychosocial support. It has been shown to have a wide range of beneficial 
effects, particularly because of its exercise component. Pulmonary rehabilitation 
implemented after a hospital admission reduces the risk of re-hospitalisation and death, and 
improves quality of life. 
Selective use of long-term oxygen therapy (LTOT)—the provision of supplemental oxygen 
therapy for 15 hours per day or more for people with COPD who have persistently low 
levels of oxygen in their blood—has been shown to improve quality of life and improve 
survival. 
Both of these therapies are among the key non-pharmacological interventions recommended 
in national and international clinical guidelines. Available evidence suggests, however, that 
pulmonary rehabilitation and LTOT are under-utilised in managing patients with COPD in 
Australia. The full extent of service provision, utilisation and under-utilisation is not known 
as there are no national data.  
This report outlines:  
• proposed indicators relevant to monitoring access to, and utilisation of, pulmonary 
rehabilitation and LTOT in Australia 
• existing data sources that may inform these indicators 
• options for data development 
• potential challenges in monitoring these therapies. 
Improved information about access to, and use of, these interventions among people with 
COPD would enable: 
• identification of opportunities for health improvement  
• measurement of the benefits derived from these interventions. 
This would form a useful basis for data development to support assessment of the 
appropriateness of use, barriers to uptake and outcomes of these therapies.  
Similar information about the provision of non-inpatient, non-procedural and non-
pharmaceutical therapies is also relevant to monitoring other chronic diseases in which these 
interventions improve quality of life and extend life. 
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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a serious long-term lung disease that 
mainly affects middle-aged and older people (ACAM 2011; Toelle et al. 2013). It is a 
progressive disease and is largely irreversible, often leading to impaired quality of life and 
sometimes to premature death. Although it is difficult to precisely determine its prevalence, 
a large international study estimated that about 1 in 13 Australians aged 40 and over have 
lung function consistent with a diagnosis of COPD (Toelle et al. 2013).  
The most important risk factor for COPD is smoking (Anthonisen et al. 1994; Doll & Peto 
1976). As smoking has historically been more common in men than women, COPD has been 
more common in men but the difference is declining in Australia (ACAM 2011). Rates of 
hospital separation for COPD are higher among Aboriginal and Torres Strait Islander people 
than among non-Indigenous Australians (ACAM 2011).  
COPD is a major cause of death in Australia. In 2011, 5,878 people were recorded as having 
died from COPD (3,278 males and 2,600 females), making it the fifth leading cause of death 
(ABS 2013).  
Direct health expenditure attributed to COPD was $929 million in the 2008–09 financial year, 
accounting for 1.3% of all health care expenditure in that year (AIHW 2010). Health 
expenditure for COPD may rise as the population ages and the number of people with the 
disease increases.  
In response to the significant burden the disease represents, the Thoracic Society of Australia 
and New Zealand and Lung Foundation Australia jointly developed and regularly revised, 
the COPD-X Plan, guidelines on the diagnosis and management of COPD (Abramson et al. 
2013; McDonald et al. 2005). The aim of these guidelines was to shift the emphasis of care to 
encompass both pharmacological and non-pharmacological interventions that are designed 
both to improve quality of life and to extend life for people with COPD (Abramson et al. 
2013). Pulmonary rehabilitation and selective use of long-term (home) oxygen therapy 
(LTOT) are among the key non-pharmacological interventions recommended in the COPD–X 
guidelines (Box 1.1) and are the focus of this report. 
Previous reports have highlighted the apparent under-utilisation of pulmonary 
rehabilitation and long-term oxygen therapy in the management of patients with COPD in 
Australia (ALF 2007; Serginson et al. 2009). These reports imply that further data may be 
needed to address this problem and to realise opportunities for health gain in this arena.  
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Box 1.1: Summary of guidelines relevant to the use of pulmonary rehabilitation 
and long-term oxygen therapy in patients with COPD 
COPD–X Plan, Australian and New Zealand Guidelines for the management of 
COPD (Abramson et al. 2013) 
• Pulmonary rehabilitation reduces dyspnoea, fatigue, anxiety and depression, 
improves exercise capacity, emotional function, health-related quality of life and 
enhances patients’ sense of self control over their condition. 
• Pulmonary rehabilitation should be offered to patients with moderate to severe 
COPD. 
• Pulmonary rehabilitation reduces hospitalisation and has been shown to be cost-
effective.  
• LTOT (≥15hours/day) prolongs life in hypoxaemic patients (arterial oxygen 
tension (paO2) <55 mm Hg). 
GOLD (Global Initiative for Chronic Obstructive Lung Diseases), Global strategy for 
the diagnosis, management and prevention of COPD (GOLD 2013) 
• All patients who get short of breath when walking on their own pace on level 
ground should be offered [pulmonary] rehabilitation. 
• The long-term administration of oxygen (>15 hours per day) to patients with 
chronic respiratory failure has been shown to increase survival in patients with 
severe resting hypox[a]emia. LTOT is indicated for patients who have: 
 a) paO2 at or below 55 mm Hg or SaO2 at or below 88% with or without 
hypercapnia confirmed twice over a three week period or 
 b) paO2 between 55 mm Hg and 60 mm Hg, or SaO2 of 88%, if there is evidence 
of pulmonary hypertension, pulmonary [o]edema suggesting congestive cardiac 
failure or polycyth[a]emia. 
American Thoracic Society/European Respiratory Society Taskforce, 
Standards for the diagnosis and treatment of patients with COPD (Celli et al. 
2004) 
• Pulmonary rehabilitation results in improvements in multiple outcome areas of 
considerable importance to the patient, including dyspnoea, exercise ability, health 
status and health care utilisation. 
• Pulmonary rehabilitation should be considered for patients with COPD who have 
dyspnoea or other respiratory symptoms, reduced exercise tolerance, a restriction 
in activities because of their disease, or impaired health status. 
• Pulmonary rehabilitation programs include exercise training, education, 
psychosocial/behavioural intervention, nutritional therapy, outcome assessment 
and promotion of long-term adherence to the rehabilitation recommendations. 
• Supplemental LTOT improves survival, exercise, sleep and cognitive performance 
in hypoxaemic patients. 
• Physiological indications for oxygen include paO2 <55mm Hg. The therapeutic goal 
is to maintain SaO2 >90% during rest, sleep and exertion. 
• If oxygen is prescribed during an exacerbation, arterial blood gases should be 
rechecked in 30–90 days. 
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What is pulmonary rehabilitation? 
Pulmonary rehabilitation is a system of care that includes a combination of exercise, 
education and psychosocial support. Individuals with COPD accounted for the largest 
proportion of people being referred for pulmonary rehabilitation (Nici et al. 2006).  
Pulmonary rehabilitation is defined as: 
’..an evidence-based, multi-disciplinary, and comprehensive intervention for 
patients with chronic respiratory diseases who are symptomatic and often have 
decreased daily life activities. Integrated into the individualized treatment of the 
patient, pulmonary rehabilitation is designed to reduce symptoms, optimize 
functional status, increase participation, and reduce health care costs through 
stabilizing or reversing systemic manifestations of the disease.’ (Nici et al. 2006;  
Ries et al. 2007) 
The combination of these interventions is important because COPD is a complex, multi-
system disease with resulting physical deconditioning, emotional responses to illness and 
social isolation, that can contribute to greater morbidity (Lacasse et al. 2006). 
Pulmonary rehabilitation programs are targeted at people who have chronic lung disease 
and who have symptoms of breathlessness or fatigue on exertion.  
The primary aims are to: 
• reduce activity limitation and participation restriction of persons with chronic lung 
diseases 
• restore patients to the highest possible level of independent functioning (Alison et al. 
2009). 
Exercise therapy within the scope of a pulmonary rehabilitation program should include 
lower limb endurance training and a home-based program. Ideally, the program should also 
include lower limb strength training and upper limb endurance and strength training 
(Alison et al. 2009) and should be provided in combination with patient education. 
Education for people with COPD, which may be provided in written, audio or video 
formats, usually covers smoking cessation, improving exercise capacity, nutrition, 
instruction on effective use of medication inhaler devices, development of action plans for 
exacerbations, coping strategies for activities of daily living or a combination of these (Effing 
et al. 2009; Monninkhof et al. 2003).  
Programs should include the following elements (Alison et al. 2009): 
• Minimum duration of 6–8 weeks. 
• Minimum of two supervised sessions each week. 
• A home exercise program should be concurrent with the supervised program, starting 
within 1–2 weeks of commencing the supervised program; the home program should be 
performed 2–3 times per week. 
• After completion of the supervised program, patients are advised to continue with home 
exercise up to 4–5 times per week at home or the gymnasium, indefinitely. 
• Home exercises need to be progressive and where possible include exercises that are 
identical to those performed in the supervised program (Alison et al. 2009).  
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Effects of pulmonary rehabilitation on health status 
in patients with COPD 
Pulmonary rehabilitation has a wide range of beneficial effects in people with COPD  
(Dunne et al. 2012; Puhan et al. 2011).  
Exercise-based pulmonary rehabilitation in patients with COPD is effective in reducing 
shortness of breath (dyspnoea) and fatigue, and in improving emotional function and control 
of the disease (Lacasse et al. 2006). When instituted after a hospital admission, it also reduces 
the risk of re-hospitalisation and death, and improves quality of life (Puhan et al. 2011). 
These benefits are mainly attributed to the exercise component of the programs. 
The effectiveness of education and psychosocial support as a part of these programs is less 
well established (Lacasse et al. 2006). However, it has been found that self-management 
education is associated with positive outcomes such as a reduction in hospital admissions, 
with no apparent detrimental effects (Effing et al. 2009). 
Access to pulmonary rehabilitation in Australia 
Available data suggest that access to pulmonary rehabilitation programs in Australia is 
limited. In 2007, there were 131 pulmonary rehabilitation programs around Australia  
(ALF 2007). Of those, 80% had a waiting list and in more than half (51%) the waiting period 
until the start of the next program was greater than four weeks. The poor accessibility was 
highlighted in a survey of 38 hospitals in New South Wales in 2007. This survey  
(NSW Agency for Clinical Innovation 2010) found: 
• only 5–10% of patients with moderate to severe COPD had accessed pulmonary 
rehabilitation services 
• over three-quarters of pulmonary rehabilitation programs had a waiting period greater 
than 4 weeks and 37% had a waiting period of greater than 2 months 
• fewer than half of the programs had capacity to provide pulmonary rehabilitation 
services for more than 100 patients per year 
• a large proportion of programs did not accept referrals from GPs, allied health or 
nursing professionals 
• 60% of programs could not offer longer-term maintenance exercise programs or follow-
up assessment or care for patients who had completed the initial program. 
An evaluation of the Lung Foundation Australia’s Breathe Easy Walk Easy program found that 
poor access and barriers to participation remain for clients in remote settings and for 
Indigenous Australians with COPD (Johnston et al. 2010).  
Based on this preliminary evidence from the survey and evaluation outlined above, it 
appears that many, and possibly the majority, of patients with COPD who could benefit from 
pulmonary rehabilitation, do not receive this service. The reasons include availability of local 
programs, transport, waiting periods, referral patterns and practitioner and patient choice.  
Estimating the extent of this under-utilisation, the associated potential for health gain, and 
barriers to access may allow policy makers to define options for interventions to improve 
access.  
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What is long-term home oxygen therapy (LTOT)? 
Long-term oxygen therapy (LTOT) refers to the provision of supplemental oxygen therapy 
for 15 to 24 hours per day, at home, over a prolonged period for people with chronic 
respiratory disease who have persistently low levels of oxygen in their blood (hypoxaemia) 
(Abramson et al. 2013).  
The level of oxygen in the blood is usually measured by performing a special blood test 
(arterial blood gases) to measure the partial pressure of oxygen in the arterial blood (paO2). 
Patients with COPD who have paO2 less than 55 mm Hg (or less than 60 mm Hg with 
evidence of certain other complications) are considered hypoxaemic and, therefore, likely to 
benefit from LTOT (McDonald et al. 2005).  
Domiciliary oxygen therapy is the inclusive term used to refer to any oxygen therapy used in 
the home (including LTOT) generally to treat episodic hypoxaemia. In contrast with 
evidence supporting LTOT, use of oxygen for treating episodic hypoxaemia has limited 
supporting evidence and is not generally subsidised.  
In Australia, this therapy is predominantly delivered using an oxygen concentrator—an 
electric-powered device that increases the concentration of oxygen of air by extracting 
nitrogen. This oxygen-enriched air is usually administered to the patient by tubing 
connected to nasal prongs (short tubes) or, less commonly, by face mask and occasionally by 
intratracheal cannula (McDonald et al. 2005; Serginson et al. 2009). 
Effects of LTOT on health status in patients with 
COPD 
LTOT improves survival and quality of life in people with hypoxaemia due to COPD (Dunne 
et al. 2012; McDonald et al. 2005; Nocturnal Oxygen Therapy Trial Group 1980). The 
principles underlying its use are summarised in Box 1.2. 
It is important to note that in patients with COPD who do not have low levels of oxygen in 
their blood, LTOT does not have beneficial effects (and does not relieve breathlessness).  
Box 1.2: What is considered good management for patients with COPD 
complicated by hypoxaemia? 
This summary is of key elements from the adult domiciliary oxygen therapy position 
statement from the Thoracic Society of Australia and New Zealand, 2005: 
• Ensure that patients meet the criteria for LTOT as defined in the guidelines. 
• Provide LTOT, defined as 15 hours or more per day. 
• Review arterial blood gases between one and three months after commencing 
oxygen therapy. 
• Review the use of oxygen therapy after one year (McDonald et al. 2005). 
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Access to LTOT in Australia 
Although the eligibility criteria for LTOT vary between jurisdictions (Serginson et al. 2009), 
all are closely based on the Thoracic Society of Australia and New Zealand’s clinical 
guidelines (McDonald et al. 2005). They all require evidence of hypoxaemia during a period 
of clinical stability, and prescription by a respiratory physician (or other nominated 
specialist).  
The use of LTOT varies within Australia, from 44 per 100,000 persons in the Northern 
Territory to 133 per 100,000 persons in Tasmania. The explanation for these differences is 
currently unknown (Serginson et al. 2009). 
Most states and territories and the Australian Government provide eligible patients with 
subsidised (or free) LTOT equipment through various medical aids subsidy schemes. Based 
on one study, the estimated total cost of LTOT funded by individual states and territories in 
2004–05 varied between $1,014 and $2,574 per patient per prescribed year (Serginson et al. 
2009).  
The Australian Government funded domiciliary oxygen therapy (which includes short-term 
oxygen and LTOT) at a cost of over $31 million a year in 2004–05 for 20,127 patients  
(includes 2001 data for Western Australia and 2003–04 data for Victoria). This cost excludes 
administrative and clinical assessment costs (Serginson et al. 2009). 
The way LTOT services are organised, funded and delivered varies widely amongst states, 
territories and regional health authorities. The uptake of LTOT also varies widely across 
Australia and there are no data that allow assessment of the appropriateness of use, the 
barriers to uptake, and the outcomes. This gap in knowledge has led to calls by the Lung 
Foundation Australia, Medical Journal of Australia and the Medical Aids Subsidy Scheme of 
Queensland for the development of a national register for LTOT (Abramson et al. 2013; 
Serginson et al. 2009). 
Purpose and scope of this report 
In summary, there is strong evidence that both pulmonary rehabilitation and LTOT are 
effective interventions in selected patients with COPD. There is some evidence suggesting 
that these interventions are under-utilised and hence optimal outcomes are not being 
achieved. The full extent of service provision, utilisation and under-utilisation is unknown as 
there are no national data.  
The purpose of this report is to: 
• describe the rationale for developing a monitoring approach for the use of pulmonary 
rehabilitation and LTOT in patients with COPD 
• develop the monitoring approach  
• describe the data sources proposed for use within the monitoring approach. 
This report presents potentially measurable indicators of the effectiveness of service 
provision in relation to pulmonary rehabilitation and LTOT for patients with COPD. For 
each suggested indicator, it outlines the rationale, the proposed source of data, and how it 
would be measured. It also proposes and justifies benchmarks against which the 
effectiveness of service provision would be assessed. 
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2. Developing a monitoring approach for 
pulmonary rehabilitation 
The following indicators for access and utilisation of pulmonary rehabilitation are proposed 
for further consideration. 
Chapter 3 describes existing or potential data sources that could serve as sources of 
information for these indicators. It presents a summary of the proposed indicators against 
possible data sources in Table 3.1. It is important to note that, for some of these indicators, no 
suitable data sources are available at present. 
Proposed indicators for monitoring pulmonary 
rehabilitation: access indicators 
Pulmonary rehabilitation indicator 1: proportion of Local Hospital 
Networks that offer pulmonary rehabilitation services 
Description  
Numerator: Number of Local Hospital Networks (LHNs) that offer pulmonary rehabilitation 
services at one or more of their facilities. 
Denominator: Number of Local Hospital Networks. 
Rationale  
As reported in the preceding chapter, access by patients with COPD to pulmonary 
rehabilitation services in Australia appears to be limited. The first step in ascertaining the 
extent of this problem is to quantify the number of services available. Pulmonary 
rehabilitation is often offered as a hospital outpatient service. Therefore, many pulmonary 
rehabilitation services will be captured in this indicator.  
Interpretation 
Each Local Hospital Network (LHN) consists of small groups of local hospitals, or an 
individual hospital, linking services within a region or through specialist networks across a 
state or territory. The aim of LHNs is to improve access to health care that is well 
coordinated, and that promotes efficient use of resources (DoHA 2011a). Australia has 137 
LHNs, each run locally, fumded nationally and accountable to national standards. 
Pulmonary rehabilitation forms part of the outpatient services that may be provided by 
LHNs. Ideally, all LHNs should offer pulmonary rehabilitation unless the service is 
adequately provided by other agencies for patients within the network. Therefore, the 
benchmark for this indicator should be near 100%. 
Inability to achieve this benchmark may indicate: 
• lack of funding for the service 
• lack of adequately trained staff 
• different prioritisation of resources 
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• the availability of adequate resources in nearby areas 
• incomplete capture of all relevant services.  
Even if 100% coverage is achieved, access by patients may be substantially limited by 
distance, given the large areas covered by some Local Hospital Networks.  
Recommended data sources  
• the Lung Foundation Australia national database of pulmonary rehabilitation programs 
• the Local Hospital Network Directory.  
Pulmonary rehabilitation indicator 2: proportion of Medicare Locals 
that have pulmonary rehabilitation services available within their 
area 
Description 
Numerator: Number of Medicare Locals that have pulmonary rehabilitation services 
available within their area. 
Denominator: Number of Medicare Locals.  
Rationale  
This indicator would provide information regarding the number of Medicare Locals that 
have pulmonary rehabilitation services available within their boundaries. It would include 
both public and private hospital-based and community-based rehabilitation clinics.  
This would be a useful companion indicator to the related Local Hospital Network indicator, 
given that the boundaries of the two entities do not always align and depending on whether 
the purpose of the indicator was to describe access within Medicare Local or Local Hospital 
Network boundaries.  
Interpretation 
Medicare Locals were created in 2011 to plan and fund extra health services across Australia. 
Sixty-one Medicare Locals were created to ensure decisions about health services could be 
made by local communities in line with local needs (DoHA 2011b). Medicare Locals are 
primary health care organisations established to coordinate primary health care delivery. 
They address local health care needs and service gaps.  
The benchmark for this indicator is 100%. 
Inability to achieve this benchmark may indicate: 
• lack of funding for the service 
• lack of adequately trained staff 
• different prioritisation of resources 
• the availability, e.g. in urban regions, of adequate resources in neighbouring areas 
• incomplete capture of all relevant services.  
Even if 100% coverage is achieved by this indicator, access by patients may be substantially 
limited by distance, given the large areas covered by some Medicare Locals.  
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Recommended data sources 
• the National Health Services Directory (NHSD) for the Medicare Locals (this will contain 
information on allied health services provided in each Medicare Local) 
• the Lung Foundation Australia’s national database of pulmonary rehabilitation 
programs (see Chapter 3, Existing data sources) 
• publicly available nationwide list of Medicare Locals. 
Pulmonary rehabilitation indicator 3: number of places available in 
pulmonary rehabilitation services per year per 100,000 population 
Description 
Numerator: Number of patient positions available per year in current pulmonary 
rehabilitation services. 
Denominator: Total Australian population (‘100,000s). 
Rationale  
As reported in the preceding chapter, fewer than half the programs surveyed in New South 
Wales in 2010 were able to admit more than 100 people per year into pulmonary 
rehabilitation programs. Most programs had waiting lists, and for 37% of programs the 
waiting time was over 12 months (NSW Agency for Clinical Innovation 2010). Hence, 
information on the number of services available does not necessarily indicate the adequacy 
of service supply. It is also necessary to assess the adequacy of supply of actual places within 
programs.  
Interpretation 
There is no consensus recommendation on a benchmark for this indicator. More work, 
including descriptive epidemiological studies, is needed to establish this benchmark. 
However, the existence of long waiting lists at many sites in a New South Wales Agency for 
Clinical Innovation 2010 survey indicates that places for pulmonary rehabilitation are 
underprovided at present, at least in that state.  
Analysis of this indicator separately by places for new attendees and places for people who 
are attending maintenance or refresher programs would add to its value for service 
planning.  
Recommended data sources 
• no existing data source (see Chapter 3 for future data development options). 
Pulmonary rehabilitation indicator 4: number of places available in 
pulmonary rehabilitation services per year per 1,000 people with 
COPD 
Description 
Numerator: Number of patient positions available per year in current pulmonary 
rehabilitation services. 
Denominator: Number of people with COPD (‘1,000s) aged 40 and over. 
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Rationale  
This indicator provides an alternative way of interpreting data about service availability, in 
this case relative to potential demand.  
Interpretation 
There is no consensus recommendation on a benchmark for this indicator. More work is 
needed to establish this.  
Recommended data sources 
• no existing data source (see Chapter 3 for data development options). 
Proposed indicators for monitoring pulmonary 
rehabilitation: utilisation indicators 
Pulmonary rehabilitation indicator 5: proportion of people with 
symptomatic COPD who have ever attended a pulmonary 
rehabilitation program 
Description 
Numerator: Number of people with symptomatic COPD (more specifically, a diagnosis of 
COPD and shortness of breath due to COPD) who have participated in a pulmonary 
rehabilitation program.  
Denominator: Number of people with symptomatic COPD. 
Rationale  
Although the strongest evidence for the effectiveness of pulmonary rehabilitation is for 
moderate to severe COPD, anyone who has COPD and is short of breath on exertion could 
potentially benefit from participating in a pulmonary rehabilitation program.  
Interpretation 
The benchmark for this indicator is 100%.  
Inability to achieve this benchmark may indicate: 
• lack of access to pulmonary rehabilitation services (see Chapter 2 ’access indicators’) 
• failure to diagnose COPD in symptomatic patients with the disease due to people with 
COPD not presenting to doctors or doctors failing to diagnose COPD in people with 
symptoms who present to them 
• failure of doctors to refer patients with symptomatic COPD to pulmonary rehabilitation 
programs 
• patients’ decision not to accept referral to a pulmonary rehabilitation program 
• incomplete capture of all relevant people attending a program.  
Recommended data sources 
• no existing data source for number of people who have attended pulmonary 
rehabilitation services (see Chapter 3 for data development options).  
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Pulmonary rehabilitation indicator 6: proportion of people with 
COPD enrolling in a pulmonary rehabilitation program in the last 12 
months who completed the program  
Description 
Numerator: Number of people with COPD who commenced a supervised pulmonary 
rehabilitation program within the last 12 months and who completed the program.  
Denominator: Number of people with COPD who commenced a supervised pulmonary 
rehabilitation program over the last 12 months. 
Rationale  
This indicator will help assess the proportion of people commencing a supervised 
pulmonary rehabilitation program who participated for a time expected to achieve clinical 
benefit. For this purpose, a standardised definition of completion of a pulmonary 
rehabilitation program needs to be developed, based on evidence about effectiveness and 
feasibility for completion by people with COPD. 
The Australian Pulmonary Rehabilitation Toolkit recommends that pulmonary rehabilitation 
programs should include a minimum of two supervised sessions per week, for at least six 
weeks (Alison et al. 2009). There is evidence, however, that longer programs may produce 
greater benefits (ACAM 2003; Ries et al. 2007). Currently, pulmonary rehabilitation 
programs vary in length and number of supervised sessions per week and the definition of 
completion of a program may vary across different programs. However, program length and 
overall attendance can be measured. An Australian survey of 147 pulmonary rehabilitation 
programs found that 65% ran for 8 weeks or longer (Johnston et al. 2011). 
Interpretation 
The benchmark for this indicator is 100%.  
Inability to achieve this benchmark may indicate: 
• Service-related factors such as poor access to transport or other costs incurred due to 
attendance 
• Patient-related factors including perceived lack of benefit, exacerbations of COPD not 
requiring hospitalisation, carer role for others in the family, co-morbid conditions that 
limit mobility, such as arthritis, or an intervening admission to hospital 
• incomplete capture of all relevant people attending a program.  
Recommended data sources 
• no existing data source. If a suitable source were identified, further work would be 
needed to define an agreed period in which a pulmonary rehabilitation program should 
reasonably be expected to be completed (see Chapter 3 for data development options). 
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Pulmonary rehabilitation indicator 7: proportion of people 
discharged from hospital after an exacerbation of COPD within the 
last 12 months, who have not completed pulmonary rehabilitation 
within the previous 12 months, and who are provided with a referral 
to pulmonary rehabilitation upon discharge 
Description 
Numerator: Number of people discharged from hospital after an exacerbation of COPD 
within the last 12 months, who have not completed pulmonary rehabilitation within the 
previous 12 months, and who are provided with a referral for pulmonary rehabilitation. 
Denominator: Number of people discharged from hospital after an exacerbation of COPD 
within the last 12 months. 
Rationale  
Exacerbations and hospitalisations are common in people with moderate to severe COPD, 
and they represent a substantial burden within the health care system. The main cost drivers 
for COPD care are Emergency Department visits and hospital admissions for acute 
exacerbations (Puhan et al. 2011).  
Pulmonary rehabilitation after an acute exacerbation of COPD reduces the risk of subsequent 
hospital admission or death (Puhan et al. 2011). Thus all patients with COPD who are 
hospitalised for an acute exacerbation will potentially benefit from a pulmonary 
rehabilitation program.  
Interpretation 
Further work is needed to identify a suitable benchmark for this indicator. Although existing 
evidence indicates that a referral should be provided for all patients discharged after a 
hospitalisation with an acute exacerbation of COPD who have not previously completed a 
pulmonary rehabilitation program, consensus needs to be established about whether to refer 
patients who have already participated in a pulmonary rehabilitation program. For example, 
a new referral may be considered if a patient has not attended a pulmonary rehabilitation 
program within the previous 12 months.  
There may be some difficulty in obtaining data for this indicator, depending on the way that 
referrals to pulmonary rehabilitation are provided within each hospital, e.g. whether the 
referral is given to the patient or to the pulmonary rehabilitation department; and also 
depending on whether such referrals are routinely documented within the hospital system.  
Recommended data sources 
• no existing data source (see Chapter 3 for data development options). 
High-risk populations 
For reporting purposes, the proposed utilisation indicators would ideally be presented by: 
• broad age group: all ages, 50–64, 65–74 and 75 and over 
• sex 
• Indigenous status 
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• a location-based measure of socio-economic disadvantage− for example, the Australian 
Bureau of Statistics Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-
Economic Disadvantage (IRSD) 
• remoteness areas (for example, Major cities, Inner/Outer regional, Remote and Very 
remote areas). 
These factors identify high-risk populations who may have poor access to, or under-
utilisation of, pulmonary rehabilitation. 
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3. Data sources for monitoring pulmonary 
rehabilitation 
Existing data sources 
AIHW National Hospital Morbidity Database 
The AIHW National Hospital Morbidity Database (NHMD) is an administrative data set 
maintained by the AIHW. It is a collection of information about care provided to patients 
admitted to Australian public and private hospitals. The database contains information on 
diagnosis, demographic characteristics, procedures performed and duration-of-stay for 
episodes of care for patients admitted to hospital (AIHW 2012b).  
Using the NHMD to inform the monitoring approach 
The database could be used to inform the denominator for the indicator measuring the 
proportion of people discharged from hospital after an exacerbation of COPD who have a 
referral to pulmonary rehabilitation. In using these data for this purpose, it would be 
important to exclude hospital separations due to death, transfer to another hospital or 
change in the type of care. 
A limitation in using these data for the monitoring approach is that the same person could be 
admitted to hospital more than once in one year, with each episode of care counting towards 
the total number of hospital separations. However, individual patients are only likely to be 
referred to pulmonary rehabilitation on one occasion per year (at most). This would result in 
over-estimation of the denominator. 
Medicare Locals and the National Health Service Directory 
A key role of Medicare Locals is to improve access to primary health care services for local 
communities by: 
• maintaining up-to-date local service directories to make it easier for patients to access the 
services they need, by linking local GPs, nursing and other health professionals, 
hospitals and aged care, Aboriginal and Torres Strait Islander health organisations  
• identifying service gaps, where local communities are missing out on services they might 
need 
• co-ordinating services (DoHA 2011b). 
Consistent with this role, Medicare Locals each have their own website and are encouraged 
to add a link on their site to the National Health Service Directory (NHSD). Medicare Locals 
and other authorised organisations will help maintain information in their respective areas 
and may add further information as national service and practitioner datasets expand 
(National Health Call Centre Network 2012). 
The directory is a newly developed, comprehensive online registry of medical services 
nationwide. It is funded by all Australian governments and will integrate with Medicare 
Locals (National Health Call Centre Network 2012). 
The directory is based on the existing Victorian model, the Victorian Human Services 
Directory (VicHSD) (National Health Call Centre Network 2012). An up-to-date register of 
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health, social and disability services in Victoria, VicHSD is designed to help health 
practitioners find services for their patients. An accompanying version for consumers is also 
available through the Better Health Channel (Better Health Channel 2012). VicHSD provides 
information about a diverse range of services including general practice, hospital and 
pharmacy. It also includes information about pulmonary rehabilitation programs 
(Department of Human Services 2012). It is planned to expand it in 2013 to provide 
information on allied health services (National Health Call Centre Network 2012). Unlike 
data from Local Hospital Networks, the NHSD will include both hospital-based and 
privately-run allied health services (National Health Call Centre Network 2012). 
Using the NHSD to inform the monitoring approach 
The directory of services within each network could be used to determine the number of 
pulmonary rehabilitation services within each Medicare Local and Local Hospital Network. 
The validity of these data will depend on allied health providers uploading their service 
details to the Medicare Local or NHSD site. 
Lung Foundation Australia’s National Database of Pulmonary 
Rehabilitation Programs 
The Lung Foundation Australia (LFA), formerly the Australian Lung Foundation (ALF), 
provides fundraising, education, advocacy and support relating to COPD and other lung 
diseases within the Australian community. In 2009, the foundation, together with the 
Australian Physiotherapy Association, developed a pulmonary rehabilitation toolkit, and 
they have been actively involved in promoting pulmonary rehabilitation in Australia (Alison 
et al. 2009). 
The foundation manages the National Database of Pulmonary Rehabilitation Programs, the 
most comprehensive register of pulmonary rehabilitation providers in Australia. The 
purpose of this register is to identify the location of pulmonary rehabilitation services for 
patients and referring doctors. The list is generated from details supplied by pulmonary 
rehabilitation providers but there is no obligation on providers to register and an unknown 
number have not provided their details to the foundation (ALF 2012). 
Using the National Database of Pulmonary Rehabilitation Programs to inform 
the monitoring approach  
The database could be used to gather data needed to inform the utilisation indicators. For 
example, it may be possible to collect data for a specified period on the number of:  
• people with COPD who attended a pulmonary rehabilitation program  
• people with COPD who complete a program  
• places available in each program.  
The database has been used previously to obtain information from pulmonary rehabilitation 
providers. In 2007, a survey of providers registered with the database collected data on the 
number of programs offered within a 12 month period, program attendance, number of 
participants in each course, and barriers to running a pulmonary rehabilitation program 
(ALF 2007). A survey in 2011 sought information on the structure and content of pulmonary 
rehabilitation programs in Australia. This national survey achieved a response rate of 83%, 
with responses from all states and territories and every geographical region (Johnston et al. 
2011). 
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Australian Burden of Obstructive Lung Disease Study 
The Australian Burden of Obstructive Lung Disease (BOLD) study measured the prevalence 
of COPD in Australia, using objective criteria based on lung function (Toelle et al. 2013). 
BOLD Australia studied 3,357 people aged 40 and over, living in 6 Australian regions.  
Using Australian BOLD data to inform the monitoring approach 
The prevalence of COPD, defined on internationally-agreed lung function criteria alone, was 
estimated to be 7.5% (Toelle et al. 2013). The study also measured the proportion of people 
reporting breathlessness on exertion. Taken together, these data could be used to determine 
the number of people with COPD who could potentially benefit from pulmonary 
rehabilitation programs. 
Options for future data development 
Population health surveys 
Population health surveys, including the Australian Bureau of Statistics’ Australian Health 
Survey and the state and territory population health surveys, collect information on reported 
diagnoses of COPD. However, self-reported diagnosis of COPD lack validity as an indicator 
of objectively confirmed COPD (Walters et al. 2011). Hence, it is unlikely that population 
surveys, without objective measures, will be useful for informing these indicators.  
Pulmonary rehabilitation registry 
A national repository of data on pulmonary rehabilitation programs could be established. 
This would be most feasible if it was limited to aggregated, de-identified data provided 
annually by an agreed set of providers of pulmonary rehabilitation services that meet 
defined criteria (as outlined in Chapter 1). An incentive or compensation for providing data 
may be required. The steps in establishing a data repository such as this would be: 
• establishment of governance arrangements 
• agreement on a national minimum dataset 
• provision of tools for acquiring the data locally and for uploading it in an aggregated 
format 
• agreement on a reporting format. 
Data from this repository could be used to inform both access and utilisation indicators.  
Improve national non-admitted patient data collections 
Currently, public reporting of non-admitted patient data (also known as outpatient care 
data) is limited to AIHW reporting using the National Public Hospital Establishments 
Database and the National Outpatient Care Database (NOCD). There may be opportunities 
to refine the classification against which these services are collated and reported to include a 
specific clinic type for pulmonary rehabilitation or more detail on patient diagnosis. This 
improved data would inform both access and utilisation indicators. 
More specifically, the current NOCD is compiled in accordance with specifications in the 
Outpatient Care National Minimum Dataset (from 2007–08) (AIHW 2013a). Selected 
hospitals throughout Australia provide records to the NOCD via state/territory health 
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authorities. These data provide counts of individual occasions of service and group services 
for 24 types of outpatient services (known as ‘clinic types’ for the purposes of the collection).  
In terms of describing access to and utilisation of pulmonary rehabilitation services, the 
NOCD has several limitations including: 
• Limited coverage of Australian hospitals− the agreed scope of the collection covers 
principal referral and specialist women’s and children’s hospitals (Peer Group A 
hospitals) or large hospitals (Peer Group B hospitals). In 2011–12 this meant that the 
NOCD covered about 79% of all individual occasions of service and 78% of group 
sessions delivered by public hospitals. It is not currently possible to estimate how these 
coverage issues would apply in the specific case of pulmonary rehabilitation clinics. 
• The data are counts of occasions of service, not persons, and a person may have multiple 
occasions of service, at a variety of outpatient clinics or departments reported in a 
reference year. 
• States and territories may differ in the extent to which outpatient services are provided 
in non-hospital settings (such as community health services) that fall outside the scope of 
the NOCD (AIHW 2013b). 
The ‘clinic type’ classification in the NOCD does not include a specific clinic type for 
pulmonary rehabilitation. Therefore the NOCD cannot currently be used within the 
proposed monitoring approach.  
The AIHW will be compiling national outpatient care data from 2013-14 onward according 
to the Non-admitted patient care aggregate NMDS. This collection expands the clinic types 
from 24 (in the existing NOCD) to 107 (according to the Tier 2 Non-Admitted Services 
classification (version 2.0)). This will not address all of the above limitations, including that 
the enhanced classification does not include a relevant clinic type for pulmonary 
rehabilitation, nor require information about the diagnosis of the patient (which could be 
useful if a more generic rehabilitation clinic type were available). 
It is, however, possible that more detailed information on non-admitted patient hospital care 
may become available in future due to various developments in relation to these data. For 
example, a Non-Admitted Patient Dataset Specification (NAP DSS) was agreed by all states 
and territories in 2011 to guide collection of more detailed information from 2012–13. 
Although this collection is not mandatory for jurisdictions and is not currently collated 
nationally for public reporting purposes, it lays the groundwork for collating more detailed 
standardised outpatient care information for public reporting in future.  
Work is also underway by the Independent Hospital Pricing Authority to improve the 
classification of subacute care services (which include rehabilitation services) (see, for 
example, AIHW 2013c). Although this work has focused to date on admitted patient care, it 
could possibly be applied in non-admitted patient settings.  
Many of these developments are being driven by the need for enhanced information to 
support the introduction of Activity Based Funding, which aims to create a more transparent 
system of delivery of services and funding for public hospitals in Australia (IHPA 2011). The 
Independent Hospital Pricing Authority (IHPA) currently collates regular state/territory 
data according to the Non-Admitted Patient Activity Based Funding Dataset Specification as 
part of its role in implementing Activity Based Funding with respect to these services (IHPA 
2013). Although this information is not provided for public reporting purposes, it is driving 
improvements in the quantity and quality of information collected about non-admitted 
patient services in Australia and could be an avenue to pursue future improvements in 
 Monitoring pulmonary rehabilitation and long-term oxygen therapy in Australia 18 
information about access to and utilisation of pulmonary rehabilitation by people with 
asthma and COPD.  
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Table 3.1: Summary of pulmonary rehabilitation indicators with recommended data sources to inform those indicators 
Indicator Description Existing data sources Evaluation of data sources 
1. Proportion of Local Hospital Networks that 
offer pulmonary rehabilitation services 
Numerator: The Lung Foundation Australia national database of 
pulmonary rehabilitation programs 
Denominator: Local Hospital Network Directory 
The Lung Foundation Australia 
national database of pulmonary 
rehabilitation programs 
Local Hospital Network Directory  
National database for pulmonary 
rehabilitation programs is 
mapped according to LHN by 
postcode or suburb 
2. Proportion of Medicare Locals that have 
pulmonary rehabilitation services available 
within their area 
Numerator: The National Health Services Directory for the Medicare 
Locals or the Lung Foundation Australia national database of 
pulmonary rehabilitation programs 
Denominator: List of Medicare Locals nationwide 
The National Health Services Directory 
for Medicare Locals or the Lung 
Foundation Australia national 
database of pulmonary rehabilitation 
programs 
List of Medicare Locals nationwide  
National database for pulmonary 
rehabilitation programs is 
mapped according to Medicare 
Local by postcode or suburb 
3. Number of places available in pulmonary 
rehabilitation services per year per 100,000 
population 
Numerator: Number of patient positions available per year in current 
pulmonary rehabilitation services 
Denominator: Total Australian population (‘100,000s) 
No existing data sources  
Australian Bureau of Statistics (ABS) 
census 2011 
Future pulmonary rehabilitation 
surveys could include a question 
on the capacity for intake per 
year 
4. Number of places available in pulmonary 
rehabilitation services per year per 1,000 people 
with COPD 
Numerator: Number of patient positions available for intake per year 
in current pulmonary rehabilitation services 
Denominator: Number of people with COPD (‘1000s) 
No existing data sources  
Burden of Obstructive Lung Diseases, 
Australia 2013  
Future pulmonary rehabilitation 
surveys could include a question 
on the capacity for intake per 
year 
5. Proportion of people with symptomatic COPD 
who have ever attended a pulmonary 
rehabilitation program 
Numerator: Number of people with symptomatic COPD who have 
ever participated in a pulmonary rehabilitation program  
Denominator: Number of people with symptomatic COPD 
No existing data sources 
Burden of Obstructive Lung Diseases, 
Australia 2013 
Future pulmonary rehabilitation 
surveys could include a question 
on the diagnosis of patients in 
the program 
6. Proportion of people with COPD enrolling in a 
pulmonary rehabilitation program in the last 12 
months who completed the program 
Numerator: Number of people with COPD who commenced a 
defined pulmonary rehabilitation program within the last 12 months, 
who completed it within 6 months  
Denominator: Number of people with COPD who commenced a 
pulmonary rehabilitation program within the last 12 months 
No existing data sources  
 
Increase the level of detail in 
non-admitted patient data 
collections to include pulmonary 
rehabilitation as a sub-type of 
allied health services 
7. Proportion of people discharged from hospital 
after an exacerbation of COPD within the last 12 
months, who have not completed pulmonary 
rehabilitation within the previous 12 months, and 
who are provided with a referral to pulmonary 
rehabilitation upon discharge 
Numerator: Number of people discharged from hospital after an 
exacerbation of COPD within the last 12 months, who have not 
completed pulmonary rehabilitation within the previous 12 months, 
and who are provided with a referral for pulmonary rehabilitation 
Denominator: Number of people discharged from hospital after an 
exacerbation of COPD within the last 12 months 
National Hospital Morbidity Database  National Hospital Morbidity 
Database would need to be 
modified to include information 
about referral to pulmonary 
rehabilitation 
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4. Developing a monitoring approach for 
long-term oxygen therapy 
The following indicators for access and utilisation of long-term oxygen therapy are proposed 
for further consideration. 
In Chapter 5 we identify the range of data sources that have been evaluated as potential 
sources of information for these indicators. We also summarise the proposed long-term 
oxygen therapy indicators against recommended data sources in Table 5.2. In presenting 
these indicators, it is important to note that there may not be a current data source available 
to inform the indicator.  
Proposed indicators for monitoring long-term 
oxygen therapy: access indicators 
LTOT indicator 1: proportion of Local Hospital Networks that offer 
LTOT services 
Description 
Numerator: Number of Local Hospital Networks (LHNs) that offer LTOT services at one or 
more of their facilities. LTOT services include clinical services for assessment and 
prescription of LTOT and also supply of subsided LTOT equipment.  
Denominator: Number of LHNs. 
Rationale 
Hospital doctors often arrange referral of eligible patients for LTOT at the time of hospital 
discharge. It is important that patients with COPD and hypoxaemia in all LHNs have 
affordable and equitable access to LTOT.  
Interpretation 
Each LHN consists of small groups of local hospitals, or an individual hospital, linking 
services within a region or through specialist networks across a state or territory. The aim of 
LHNs is to improve access to health care that is well coordinated, and that promotes efficient 
use of resources (DoHA 2011a). Each of the LHNs is run locally, funded nationally and 
accountable to national standards; 137 have been agreed upon by all states and territories. 
The benchmark for this indicator should be close to 100%. All LHNs should offer LTOT 
except if the service is adequately provided by other agencies for patients within the 
network.  
Inability to achieve this benchmark may indicate: 
• inadequate provision of this service 
• the availability of adequate resources in nearby areas (mainly applies to urban areas) 
• incomplete capture of all relevant services.  
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Even if 100% coverage is achieved, access by patients may be substantially limited by 
distance, given the large areas covered by some LHN.  
Recommended data sources 
• administrative data associated with State and Territory and National Funding for LTOT 
and their LTOT suppliers and LHN information from the National Health Services 
Directory (refer to Chapter 3, ‘Existing data sources’). 
LTOT indicator 2: Proportion of Medicare Locals that have LTOT 
services available within their area 
Description 
Numerator: Number of Medicare Locals that have LTOT services available within their area. 
LTOT services include clinical services for assessment and prescription of LTOT and also 
supply of subsided LTOT equipment. 
Denominator: Number of Medicare Locals.  
Rationale 
This indicator would provide information regarding the number of Medicare Locals that 
have LTOT services available within their boundaries. It would include both hospital-based 
and privately run specialist and general practice clinics that may provide LTOT services. It is 
important that patients with COPD and hypoxaemia in all Medicare Local areas have 
affordable and equitable access to LTOT. 
This would be a useful companion indicator to the related Local Hospital Network indicator, 
given that the boundaries of the two entities do not always align and depending on whether 
the purpose of the indicator was to describe access within Medicare Local or Local Hospital 
Network boundaries.  
Interpretation 
Medicare Locals were created in 2011 to plan and fund extra health services in communities 
across Australia. Sixty-one Medicare Locals were created to ensure decisions about health 
services could be made by local communities in line with local needs (DoHA 2011b). 
Medicare Locals are primary health care organisations established to coordinate primary 
health care delivery. They address local health care needs and service gaps. 
The benchmark for this indicator is 100%. 
Inability to achieve this benchmark may indicate: 
• inadequate provision of this service 
• the availability of adequate resources in nearby areas (mainly applies to urban areas) 
• incomplete capture of all relevant services.  
Even if 100% coverage is achieved, access by patients may be substantially limited by 
distance, given the large areas covered by some Medicare Locals.  
Recommended data sources 
• State and Territory and National Funding for LTOT and their LTOT suppliers and 
Medicare Local nationwide list. 
 Monitoring pulmonary rehabilitation and long-term oxygen therapy in Australia 23 
Proposed indicators for monitoring long-term 
oxygen therapy: utilisation indicators 
LTOT indicator 3: proportion of people with COPD and hypoxaemia 
who are currently using LTOT 
Description 
Numerator: Number of people with COPD and hypoxaemia, defined according to TSANZ 
guidelines (McDonald et al. 2005), who are using LTOT as a part of their management. 
Denominator: Number of people with COPD and hypoxaemia (defined according to TSANZ 
guidelines) who are non-smokers. 
Rationale 
Use of LTOT is associated with improved survival and quality of life in patients with COPD 
and hypoxaemia (see Chapter 1, ‘Effects of LTOT on health status in patients with COPD’) 
and is therefore recommended for all such patients who are not currently smoking 
(McDonald et al. 2005; Abramson et al. 2013).  
Interpretation 
The benchmark for this indicator is 100%. 
Inability to achieve this benchmark may be due to any of the following causes: 
• doctors’ failure to diagnose COPD in people who have this condition and also have 
hypoxaemia 
• doctors’ failure to identify hypoxaemia in people with COPD and hypoxaemia 
• respiratory physicians’ failure to consider LTOT for patients who are diagnosed with 
COPD and hypoxaemia and who are non-smokers 
• refusal by patients to accept a recommended prescription for LTOT from a respiratory 
physician  
• failure of the designated subsidy scheme to provide subsidy for the equipment 
• failure of the patient to make any co-payment required for the provision or equipment 
• patient discontinuing use of the LTOT  
• persistent failure of patient to adhere to LTOT for 15 hours or more per day, resulting in 
withdrawal of service. 
Recommended data sources  
• State and Territory and National Funding for LTOT.  
LTOT indicator 4: proportion of people prescribed LTOT for COPD 
who are using it 15 hours or more per day 
Description 
Numerator: Number of people who are using LTOT 15 hours or more per day. 
Denominator: Number of people who are using LTOT.  
 Monitoring pulmonary rehabilitation and long-term oxygen therapy in Australia 24 
Rationale 
Guidelines recommend that LTOT be used for 15 hours or more per day. This 
recommendation is based on evidence from two randomised controlled trials, which showed 
that beneficial effects on survival were achieved with this level of usage (Medical Research 
Council Working Party 1981; Nocturnal Oxygen Therapy Trial Group 1980). It is important 
to measure the extent to which users are adhering to this recommendation.  
Interpretation 
The benchmark for this indicator is 100%. 
Inability to achieve this benchmark may be due to: 
• failure by the prescribing physician or clinical team to provide appropriate education 
about the use of LTOT 
• adverse effects of LTOT (such as drying of nasal mucosa) that mitigate against adherence 
to therapy 
• failure by the patient to adhere to recommended LTOT for other reasons 
• incomplete capture of all people receiving LTOT.  
Recommended data sources 
• State and Territory and National Funding for LTOT.  
LTOT indicator 5: proportion of people commenced on LTOT who 
have a scheduled review within four months of supply 
Description 
Numerator: Number of people commenced on LTOT who have a review within four months 
of supply. 
Denominator: Number of people commenced on LTOT. 
Rationale 
The TSANZ position statement in Box 1.2 stipulates that a review of LTOT should occur 
within one to three months of commencing the therapy. Some jurisdictions require review at 
different time intervals and some not at all but most have a review within four months of 
initial supply. The importance of this review is to determine that the hypoxia was not due to 
the COPD being unstable during initial prescription and also to determine if the treatment 
has been worthwhile, appropriately applied and utilised, and should be continued or 
abandoned (McDonald et al. 2005). 
Interpretation  
The benchmark for this indicator is 100%. 
Inability to achieve this benchmark may indicate: 
• failure of the treating clinical team to schedule a review 
• failure of patient to attend a scheduled review 
• incomplete capture of all people receiving LTOT.  
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Recommended data sources  
• State and Territory and National Funding for LTOT. 
LTOT indicator 6: proportion of people who are using LTOT and 
have a scheduled review every 12 months 
Description 
Numerator: Number of people who have used LTOT for more than 18 months who have a 
scheduled clinical review within the preceding 12 months.  
Denominator: Number of people who have used LTOT for more than 18 months. 
Rationale 
In Box 1.2 the TSANZ position statement recommends that a person on LTOT should be 
reviewed annually, or more often according to their clinical situation (McDonald et al. 2005).  
Interpretation 
The benchmark for this indicator is 100%. 
Inability to achieve this benchmark may indicate: 
• failure of the treating clinical team to schedule a review 
• failure of patient to attend a scheduled review 
• incomplete capture of all people receiving LTOT.  
Recommended data sources 
• State and Territory and National Funding for LTOT.  
High-risk populations 
The proposed utilisation indicators to identify high-risk populations with poor access to, or 
under-utilisation of, LTOT would be ideally presented by: 
• broad age group: all ages, 50–64, 65–74 and 75 and over  
• sex 
• Indigenous status 
• a location-based measure of socio-economic disadvantage−for example, the Australian 
Bureau of Statistics Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-
Economic Disadvantage (IRSD) 
• remoteness areas (for example, Major cities, Inner/Outer regional, Remote and Very 
remote areas). 
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5. Data sources for monitoring LTOT 
Existing data sources 
State and Territory and National Funding for LTOT 
Several agencies fund and deliver LTOT for eligible patients. In most states and territories, 
the main funding agency is the jurisdiction’s department of health. However, the 
Department of Veterans Affairs provides LTOT for eligible Australian war veterans and the 
Department of Health funds it for those in aged care facilities.  
Each of these agencies requires a prescription or referral for LTOT from the treating clinician, 
who is usually a respiratory physician, but in some jurisdictions can be a respiratory Nurse 
Practitioner or General Practitioner. This referral includes clinical information that is used by 
the agencies to assess the client’s eligibility under funding guidelines. If the client is deemed 
to be eligible (see Chapter 1,’Access to LTOT in Australia’), the agency then sends the referral 
to an oxygen supplier, who delivers the equipment to the client.  
Using the State and Territory and National Funding data to inform the 
monitoring approach 
Some of the data used to assess eligibility are recorded by the funding agencies. Potentially, 
these data could be used to inform the indicators on utilisation of LTOT. However, not all the 
information on the referral forms is recorded in the database. Furthermore, the available 
information varies between jurisdictions and agencies. For example, although the majority of 
funding agencies require regular reviews (initial 1–2 months and annual reviews) of LTOT, 
they are not consistent nationwide. In addition, given the variability across jurisdictions in 
the way LTOT services are funded and delivered, it would be necessary to consider all 
funding data combined to obtain an overall picture of utilisation and access.  
Effective use of these referral data for monitoring LTOT utilisation would require agreement 
on a national minimum dataset. The data elements that are relevant to the proposed 
indicators for LTOT are listed in Table 5.1, along with information on what is currently 
recorded in the referral forms and in databases in states/territories and the national 
Department of Veteran’s Affairs data collection.  
Oxygen suppliers in Australia 
Several companies supply oxygen concentrators and portable oxygen in Australia. They 
usually have contracts with funding agencies to supply specified clients. Clients may also 
buy or rent an oxygen concentrator or portable oxygen device directly from a supplier. This 
is most likely to occur if the funding agency decides that the client is ineligible for funding 
support on clinical or financial grounds but may also occur when the treating clinician is 
unaware of the availability of a subsidised program or unable to access it. 
Using data from oxygen suppliers to inform monitoring approach 
Most oxygen concentrators have an in-built device for recording the number of hours the 
device has been operating. Many oxygen suppliers record this information which can be fed 
back to the government funding agencies. Clinicians and agencies use this information to 
assess the client’s adherence with LTOT, but this is not universal. If collected regularly and 
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consistently, this information could be used to inform the indicator measuring the 
proportion of people who are using LTOT 15 hours or more per day. 
Australian Burden of Obstructive Lung Disease Study 
The Australian Burden of Obstructive Lung Disease (BOLD) study (Toelle et al. 2013) 
measured the prevalence of COPD using objective criteria-based lung function measured in 
3,357 people aged 40 and over living in 6 Australian regions.  
Using BOLD, Australia to inform the monitoring approach 
The prevalence of COPD in Australia was estimated to be 7.5% (Toelle et al. 2013). Further 
work would be needed to estimate the prevalence of hypoxaemia severe enough to require 
LTOT among people with COPD. These data are required to estimate the denominator for 
the indicators of utilisation of LTOT. 
Options for data development 
Health measurement survey 
There are no data on the prevalence of hypoxaemia in people with COPD. The recent BOLD 
survey has measured the prevalence of COPD, based on measurement of spirometric lung 
function in a general population sample (Toelle et al. 2013). It may be possible to include 
measurement of oxygen saturation by pulse oximetry (a cheap non-invasive test) in future 
similar surveys. It may also be possible to include measurement of spirometric lung function 
and oxygen saturation in a future national health measurement survey.  
These data are required to estimate the denominator for the utilisation indicators.  
Population health surveys 
Existing population health surveys, including the National Health Survey or the state and 
territory population health surveys, could be adapted to include questions that identify 
people who are using LTOT.  
These data would be useful for estimating the numerator of the utilisation indicators.  
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Table 5.1: Summary of data variables recorded by state and territory referral form and database relevant to proposed LTOT indicators 
Data variables          Proposed Indicators 
State/Territory 
referral forms 
and guidelines 
and databases 
Diagnosis ABG(a) 
at 
initial 
Prescribed 
15 hours or 
more per 
day 
Type of 
equipment 
Review 
at 6–8 
weeks 
after 
supply 
ABG(a) 
at 3 
month 
review 
Review 
every 
12 
months 
ABG(a) or 
oximetry 
at 12 
month 
review 
Record 
of 
hours 
of use 
People with 
COPD and 
hypoxaemia 
currently 
using LTOT 
Proportion 
using LTOT 
15 hours or 
more per 
day 
Review 
at 6–8 
weeks 
Review 
every 
12 
months 
Enable NSW 
Referral form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Database              
Statewide 
Equipment 
Program VIC 
             
Referral form              
Database        * *     
Medical Aids 
Subsidy 
scheme Qld 
             
Referral form        n.a.      
Database         *     
Department of 
Health WA 
             
Referral form              
Database (Silver 
Chain)              
Table continued  
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Table 5.1 (continued): Summary of data variables recorded by state and territory referral form and database relevant to proposed LTOT indicators 
Data variables          Proposed Indicators 
State/Territory 
referral forms 
and guidelines 
and databases 
Diagnosis ABG(a) 
at 
initial 
Prescribed 
15 hours or 
more per 
day 
Type of 
equipment 
Review 
at 6–8 
weeks(a) 
after 
supply 
ABG(b) 
at 3 
month 
review 
Review 
every 12 
months 
ABG(a) or 
oximetry 
at 12 
month 
review 
Record 
of 
hours 
of use 
People with 
COPD and 
hypoxaemia 
currently 
using LTOT 
Proportion 
actual use 
LTOT 15 
hours or 
more / day 
Review 
at 6–8 
weeks 
Review 
every 
12 
months 
Department of 
Health SA 
             
Referral form              
Database n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a 
Royal Hobart 
Hospital, TAS 
             
Referral form              
Database              
ACT Domiciliary 
oxygen 
respiratory 
support scheme 
             
Referral form              
Database              
Disability 
equipment 
program NT 
             
Referral form              
Database              
DVA              
Referral form              
Database n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a  n.a 
(a) Queensland conducts a review within 4 months of supply. (b) Arterial blood gases. 
Note * indicates that variable is collected elsewhere but not on current database. 
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Table 5.2: Summary of LTOT indicators with recommended data sources to inform those indicators 
Indicator Description Existing databases Evaluation of databases 
1. Proportion of Local Hospital 
Networks that offer LTOT 
services 
Numerator: Number of Local Hospital Networks that offer 
LTOT services at one or more of their facilities 
Denominator: Number of Local Hospital Networks 
State and Territory and National Funding for LTOT 
Local Hospital Network Directory database 
Identify suppliers in each 
jurisdiction and map according to 
LHN by postcode or suburb 
2. Proportion of Medicare 
Locals that have LTOT 
services available within their 
area 
Numerator: Number of Medicare Locals that have LTOT 
services available within their area 
Denominator: Number of Medicare Locals 
State and Territory and National Funding for LTOT 
Medicare Local nationwide list  
Identify suppliers in each 
jurisdiction and map according to 
Medicare Local by postcode or 
suburb 
3. Proportion of people with 
COPD and hypoxaemia who 
are currently using LTOT 
Numerator: Number of people with COPD and hypoxaemia 
who are using LTOT as a part of their management 
Denominator: Number of people with COPD and hypoxaemia 
who are non-smokers. 
State and Territory and National Funding for LTOT 
No current data sources 
Development of a national 
minimum dataset to ensure that 
the data variables Diagnosis and 
ABG at initial which are present 
on the referral forms are included 
in each jurisdiction’s database 
4. Proportion of people 
prescribed LTOT for COPD 
who are using it 15 hours or 
more per day 
Numerator: Number of people who are using LTOT 15 hours 
or more per day 
Denominator: Number of people who are using LTOT  
 State and Territory and National Funding for LTOT  
 State and Territory and National Funding for LTOT 
Development of a national 
minimum dataset to ensure that 
the data variables Prescribed 15 
hours or more per day and 
Record of hours of use are 
included in each jurisdiction’s 
database 
5. Proportion of people 
commenced on LTOT who 
have a scheduled review 
within four months of supply 
Numerator: Number of people commenced on LTOT who have 
a review within four months of supply 
Denominator: Number of people commenced on LTOT 
 State and Territory and National Funding for LTOT 
 State and Territory and National Funding for LTOT 
Development of a national 
minimum dataset to ensure that 
the data variable Review before 4 
months which is present on most 
referral forms and state/territory 
guidelines is included in each 
jurisdiction’s database 
6. Proportion of people who 
are using LTOT and have a 
scheduled review every 12 
months 
Numerator: Number of people who have used LTOT for more 
than 18 months who have a scheduled clinical review within 
the preceding 12 months.  
Denominator: Number of people who have used LTOT for 
more than 18 months. 
 State and Territory and National Funding for LTOT 
 State and Territory and National Funding for LTOT 
Development of a national 
minimum dataset to ensure that 
the data variable Review every 12 
months which is present in most 
state/territory guidelines is 
included in each jurisdiction’s 
database 
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6. Summary and implications for other 
chronic diseases 
There is strong evidence that both pulmonary rehabilitation and LTOT are effective 
interventions in selected patients with COPD. However, some reports suggest that these 
interventions are under-utilised and that optimal outcomes are therefore not being achieved. 
Hence, there is value in monitoring the provision of these therapies. 
Since there are no existing national data for these interventions, the full extent of service 
provision, utilisation and under-utilisation is unknown. This is further complicated by the 
absence of agreed, standardised definitions of pulmonary rehabilitation and LTOT, and the 
lack of uniform registration of episodes of provision of these therapies linked to individual 
patients. 
The first step in developing and informing a monitoring approach that could be used to 
evaluate the effectiveness, efficiency, accessibility and quality of service provision is to 
decide what is important to monitor. This report has identified and defined several access 
and utilisation indicators that would be a useful basis for the evaluation of pulmonary 
rehabilitation services and LTOT therapies. 
Recommended pulmonary rehabilitation indicators are: 
1. Proportion of Local Hospital Networks that offer pulmonary rehabilitation services 
2. Proportion of Medicare Locals that have pulmonary rehabilitation services available 
within their area 
3. Number of places available in pulmonary rehabilitation services per year per 100,000 
population 
4. Number of places available in pulmonary rehabilitation services per year per 1,000 
people with COPD 
5. Proportion of people with symptomatic COPD who have ever attended a pulmonary 
rehabilitation program 
6. Proportion of people with COPD enrolling in a pulmonary rehabilitation program in the 
last 12 months who completed the program 
7. Proportion of people discharged from hospital after an exacerbation of COPD within the 
last 12 months, who have not completed pulmonary rehabilitation within the previous 12 
months, and who are provided with a referral to pulmonary rehabilitation upon 
discharge. 
Recommended LTOT indicators are: 
1. Proportion of Local Hospital Networks that offer LTOT services 
2. Proportion of Medicare Locals that have LTOT services available within their area 
3. People with COPD and hypoxaemia who are currently using LTOT 
4. Proportion of people prescribed LTOT for COPD who are using it 15 hours or more per 
day 
5. Proportion of people commenced on LTOT who have a scheduled review within four 
months of supply 
6. Proportion of people who are using LTOT and have a scheduled review every 12 months. 
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Limited data are available to enable the monitoring of these proposed indicators and, hence, 
evaluate provision of pulmonary rehabilitation and LTOT services in Australia.  
Key options for data development 
This report has outlined several suggestions for enhancing information about pulmonary 
rehabilitation and LTOT services. These include: 
• enhancing the national admitted patient hospital minimum dataset to incorporate more 
data variables from referral/discharge forms 
• including relevant questions in population health surveys 
• mapping suppliers of LTOT and providers of pulmonary rehabilitation programs by 
Local Hospital Networks or Medicare Local boundaries 
• increasing the level of detail in non-admitted hospital patient data collections. 
Implications for other chronic diseases 
This report has highlighted the importance of two non-inpatient, non-procedural and non-
pharmaceutical components of care for patients with COPD: pulmonary rehabilitation and 
LTOT. The findings may be relevant to understanding the management of other acute and 
chronic diseases, for example through:  
• rehabilitation programs for patients with cardiac, neurological, and musculoskeletal 
diseases 
• providing physical aids for people with neurological and musculoskeletal chronic 
diseases 
• providing dialysis for patients with end-stage renal disease 
• psycho-social counselling for people with psychiatric disease 
• vaccinating patients with a range of chronic disease. 
Effective chronic disease management generally involves coordinated care by health 
professionals across various hospital and community settings and involving different types 
of treatment and facilitation of access to a range of aids, equipment and further advice where 
appropriate. Government and non-government agencies evaluating the provision of care for 
patients with chronic disease and formulating policy to improve the provision of care for 
these patients would benefit from improved data about these broad range of services.  
  
 Monitoring pulmonary rehabilitation and long-term oxygen therapy in Australia 33 
Glossary 
Aboriginal: A person of Aboriginal descent who identifies as an Aboriginal and is accepted 
as such by the community in which he or she lives. 
Arterial blood gases: A test performed on arterial blood to measure the partial pressures and 
concentrations of carbon dioxide and oxygen along with the pH and bicarbonate level.  
Benchmarking: A continuous process of measuring quality or performance against the 
highest standards. 
Chronic obstructive pulmonary disease (COPD): A preventable and treatable disease with 
some significant extra-pulmonary effects that may contribute to the severity in individual 
patients. Its pulmonary component is characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually progressive and associated with an abnormal 
inflammatory response of the lung to noxious particles or gases (GOLD 2013). It may be 
characterised by emphysema and/or chronic bronchitis. By far the greatest cause is cigarette 
smoking. 
Dyspnoea: breathlessness or shortness of breath 
Health survey: A research method in which health information is collected from participants 
at a point in time. In population health monitoring, this typically involves selecting a 
representative sample of the population and administering questionnaires to the 
participants. This can be done in person, over the phone or by post. Some surveys include 
physiological measurements. 
Hypercapnia: Presence of excess carbon dioxide 
Hypoxaemic: Deficient oxygenation of the blood (note that the TSANZ guidelines define a 
level of hypoxaemia that is required to qualify for LTOT (McDonald et al. 2005) 
Indicator: A key statistical measure selected to help describe (indicate) a situation concisely, 
track progress and performance, and act as a guide to decision-making. It may have an 
indirect meaning as well as a direct one; for example, Australia’s overall mortality rate is a 
direct measure of mortality but is often used as a major indicator of population health. 
Indigenous: A person who identifies themselves as an Aboriginal or Torres Strait Islander.  
Local Health Network: small groups of local hospitals, or an individual hospital, linking 
services within a region or through specialist networks across a state or territory. There are 
137 Local Hospital Networks in Australia. 
Long-term oxygen therapy (LTOT): administration of oxygen as a medical intervention 
prescribed 15 hours or more per day. 
Medicare Local: primary health care organisations in Australia that link local GPs, nursing 
and other health professionals, hospitals and aged care, Aboriginal and Torres Strait Islander 
health organisations within 61 defined Medicare Locals. 
Oedema: swelling caused by fluid in the body’s tissues. 
Polycythaemia: a condition in which there are too many red blood cells in the blood 
circulation. 
Pulmonary rehabilitation: A system of care that includes education, exercise training, 
nutrition counselling and psychosocial support. Exercise training includes aerobic training of 
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upper and lower limbs and trunk muscles, flexibility and muscle strength as well as teaching 
breathing control. Education improves the patient’s knowledge about breathing and assists 
smokers to quit and sustain quitting. Patients are trained to optimise activities and nutrition, 
gain control over anxiety, panic or depression, and use appropriate medications and 
therapeutic devices effectively (Frith 2008). 
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Monitoring pulmonary rehabilitation and 
long-term oxygen therapy for people with 
chronic obstructive pulmonary disease 
(COPD) in Australia
Chronic obstructive pulmonary disease (COPD) is a 
major cause of death and disability in Australia. While 
pulmonary rehabilitation and long term oxygen therapy 
are recommended treatments for COPD, there is 
currently no national information about the supply and 
use of these therapies. This report outlines a proposed 
approach to monitoring access to, and utilisation of, 
these therapies, by capitalising on existing data sources 
and identifying data development opportunities.
